An interventional study of INR self-management in Atrial Fibrillation and Flutter and Mechanical Mitral Valve Prosthesis, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-05.
Sponsored by Cairo University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Atrial Fibrillation with a site in Egypt — 9 open to participants now, 12 under way, 1 of them phase 3. Atrial Fibrillation · Egypt.
Among the 33 studies in Atrial Fibrillation with a site in Egypt, this one is the 5th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2023, is one of 8 with no phase, reaches primary completion later than 4 of the 11 other live ones, and was the 24th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →9 of the 33 studies in Atrial Fibrillation with a site in Egypt are open now. Recruiting first, the newest first:
University of L'Aquila · Sites in Egypt, Croatia, Denmark and 12 more countries
Ages 18+
Assiut University · Sites in Egypt
Ages 20–70 · Healthy volunteers
Helwan University · Sites in Egypt
Ages 18–74
Ain Shams University · Sites in Egypt
Ages 18–75
Sohag University · Sites in Egypt
Ages 18+
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 5 · Phase 4 4
First in 2007; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 586 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 180 across the 21 interventional studies, 200 across the 12 observational. Of the 15 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 33 have an industry lead sponsor. The 10 most frequent:
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Cairo University has 2 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
3 of the studies in Atrial Fibrillation with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07640919Sohag UniversityPatterns of Cardiac Arrhythmia in Patients With Chronic Kidney Disease | 2026-12-20 |
| NCT06823466University of L'AquilaAdvancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants | 2027-02-12 |
| NCT07568964Ain Shams UniversityEvaluation of Probiotics' Effect on Atrial Fibrillation Recurrence in Patients Undergoing Cardioversion | 2027-05-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 33 studies in Atrial Fibrillation with a site in Egypt, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Oral anticoagulation (OAC) is indicated in a wide variety of clinical conditions including atrial fibrillation (AF), mechanical valve prosthesis (MVP), deep vein thrombosis and pulmonary embolism. Although direct OAC has replaced vitamin K antagonists (VKA) in non-valvular AF due to lower bleeding risk, it's still recommended to use VKA specifically in cases of valvular AF, MVP and anti-phospholipid syndrome.
VKA has a narrow therapeutic range and multiple drug interactions causing unpredicted pharmacodynamics. This requires regular monitoring of the international normalized ratio (INR) level to ensure it's in the target therapeutic range and prevent extreme values that may result in thrombo-embolic events or sometimes fatal bleeding.
Self-INR monitoring and management have emerged recently as a safe cost-effective alternative to standard management, with evidence of tighter control of INR, reduction of thrombo-embolic events, and improving treatment-related quality of life. However, there are no specific criteria for patient selection. Whether the level of education and other social factors would affect the outcomes of self-management is still not clear.
Owing to the wide geographical area served by Aswan Heart Center, many patients have to cover long distances to follow up their INR and seek medical advice regarding adequate dose modification. This may result in reluctance and non-compliance to clinic visits and INR testing. Proper education, training and providing an alternative near place to measure the INR and self-adjust warfarin dose is expected to improve patient adherence and compliance.
Study Methods
Exclusion criteria:
Individual informed consent will be taken from every candidate for the study. The candidates will have the right to withdraw from the study at any time without any changes in the clinical service provided to them.
A-Medical history including:
Age, gender, indication of VKA. Data about valve surgery including date, location and type of valve. Past history of any chronic medical conditions, thrombo-embolic or bleeding events. Past history of blood transfusion.
B-Social history including:
Marital status, occupation, level of education and self-care capability.
C- Clinical examination including:
Assessment of body weight, height and body mass index calculation. Vital signs including blood pressure measurement using standard technique, assessment of the pulse, respiratory rate and temperature.
C- Blood sample and chemistry:
Blood tests will be done for all participants initially and at the end of the study. Laboratory workup will include complete blood count, liver, kidney function tests and electrolytes.
F- Electrocardiography (ECG):
12-lead ECG will be done for all participants initially and the end of the study to confirm rhythm.
H- Echocardiography:
I. Randomization:
Self-management arm:
Standard monitoring arm:
K. Follow-up:
Standard monitoring group will be reviewed on monthly basis or less according to INR test results. Self-management group will be reviewed 6 months after randomization, with the following data to be obtained:
Bleeding events will be graded according to BARC classification
Type 4: Coronary artery bypass graft-related bleeding. Type 5: Fatal bleeding. 4. Thrombo-embolic event: defined as mechanical valve thrombosis confirmed by trans-oesophageal echocardiography (prosthesis-related mass, elevated gradients, stuck leaflet motion), cerebrovascular stroke, peripheral embolism causing acute limb ischemia.
In case of mortality, data will be collected about the date and cause of mortality, and any reported clinical events before mortality.
Data will be presented and used without inference to the name or personal data of the patients. All patient records will be handled in accordance to hospital and national confidentiality protocols.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The participants will be responsible to monitor their INR regularly and adjust the warfarin dose by themselves accordingly, without seeking medical advice from medical personnel for 6 months. All participants will receive full education class of minimum one-hour time and training about how to interpret INR levels and adjust their medication dose according to a pre-determined dose-INR schedule.
Other: INR self-management
Regular INR monitoring and seeking medical advice at Aswan Heart Centre
will receive full education class of minimum one-hour time and training about how to interpret INR levels independently and adjust their medication dose according to a pre-determined dose-INR schedule.
Time and proportion of INR in therapeutic range
Time in therapeutic range and percentage of test results in therapeutic range
Time frame: 6 months
All-cause mortality
Death from any cause
Time frame: 6 months
Thrombo-embolic events
Stroke, valve thrombosis or peripheral embolism
Time frame: 6 months
Major bleeding
Overt bleeding that requires medical intervention or hospitalization
Time frame: 6 months
Minor bleeding
Self-controlled bleeding that doesn't need seeking medical advice
Time frame: 6 months
Frequency of testing
Number of tests per specific time range
Time frame: 6 months
Plan to share: Yes
Supporting information: Study protocol, Informed consent form, Clinical study report
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Dec 2024, 12 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 12 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.